Pacira BioSciences (NASDAQ:PCRX) Price Target Lowered to $17.00 at Barclays

Pacira BioSciences (NASDAQ:PCRX) had its price objective cut by Barclays from $25.00 to $17.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Other equities research analysts also recently issued reports about the company. Raymond James downgraded Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. Truist Financial downgraded Pacira BioSciences from a “buy” rating to a “sell” rating and dropped their target price for the stock from $30.00 to $8.00 in a report on Tuesday, August 13th. Piper Sandler downgraded Pacira BioSciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $42.00 to $11.00 in a report on Monday, August 12th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and set a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Pacira BioSciences presently has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Trading Up 1.4 %

Pacira BioSciences stock opened at $16.60 on Tuesday. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The business’s fifty day simple moving average is $15.75 and its two-hundred day simple moving average is $20.74. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $35.95. The company has a market capitalization of $766.42 million, a price-to-earnings ratio of -8.18 and a beta of 0.82.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Pacira BioSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock valued at $149,413,000 after acquiring an additional 14,960 shares during the period. Pacer Advisors Inc. grew its position in shares of Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after acquiring an additional 2,799,434 shares during the period. Renaissance Technologies LLC increased its stake in shares of Pacira BioSciences by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock worth $59,114,000 after purchasing an additional 184,000 shares in the last quarter. State Street Corp raised its holdings in Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock worth $30,311,000 after purchasing an additional 110,162 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after purchasing an additional 198,936 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.